Eyelid edema as first manifestation of anti‐MDA5 positive dermatomyositis with rapidly progressive interstitial lung disease: A case report

A 46-year-old Caucasian male was referred for evaluation of bilateral palpebral and periorbital edema without pruritus. His symptoms started suddenly, with progressive swelling of the left eyelid three months earlier. Previously considered diagnoses included angioedema, contact dermatitis, cellulitis and Morbihan disease. However, neither treatment with topical corticosteroids and calcineurin inhibitors, nor therapy with low-dose systemic corticosteroids, penicillin, doxycyClinical Letter

[1]  K. Hirata,et al.  Correlation between disease activity and serum ferritin in clinically amyopathic dermatomyositis with rapidly-progressive interstitial lung disease: a case report , 2018, BMC Research Notes.

[2]  R. Vleugels,et al.  Anti‐melanoma differentiation–associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features , 2017, Journal of the American Academy of Dermatology.

[3]  M. Fujimoto,et al.  Antimelanoma differentiation‐associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis , 2017, The British journal of dermatology.

[4]  R. Hohlfeld,et al.  Guidelines on dermatomyositis – excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology , 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[5]  F. Liotta,et al.  MDA5-positive dermatomyositis: an uncommon entity in Europe with variable clinical presentations , 2015, Clinical and Molecular Allergy.

[6]  L. Chung,et al.  Cutaneous Ulceration in Dermatomyositis: Association With Anti–Melanoma Differentiation–Associated Gene 5 Antibodies and Interstitial Lung Disease , 2015, Arthritis care & research.

[7]  N. McHugh,et al.  Myositis Specific and Associated Autoantibodies in the Diagnosis and Management of Juvenile and Adult Idiopathic Inflammatory Myopathies , 2014, Current Rheumatology Reports.

[8]  E. Chan,et al.  Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. , 2014, Clinical and experimental rheumatology.

[9]  T. Fujita,et al.  Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease , 2013, Modern rheumatology.

[10]  M. Akiyama,et al.  Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. , 2012, Rheumatology.

[11]  L. Chung,et al.  The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. , 2011, Journal of the American Academy of Dermatology.

[12]  T. Nishikawa,et al.  Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. , 2005, Arthritis and rheumatism.